Phaseline

Companies › IDP Discovery Pharma

IDP Discovery Pharma: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jul 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IDP-121
cMyc protein antagonist
MYCPhase 1Multiple Myeloma (MM); Small Cell Lung Cancer ( SCLC )Jul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05908409IDP-121Phase 1Multiple Myeloma (MM)OncologyDec 2025
NCT07864207IDP-121Phase 1Small Cell Lung Cancer ( SCLC )OncologyJul 2028

Targets

MYC (1)

Companies with the same targets

Peptomyc

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.